These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32173485)

  • 21. The therapeutic role of lactobacillus and montelukast in combination with metformin in diabetes mellitus complications through modulation of gut microbiota and suppression of oxidative stress.
    El-Baz AM; Shata A; Hassan HM; El-Sokkary MMA; Khodir AE
    Int Immunopharmacol; 2021 Jul; 96():107757. PubMed ID: 33991997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Montelukast protects against renal ischemia/reperfusion injury in rats.
    Sener G; Sehirli O; Velioğlu-Oğünç A; Cetinel S; Gedik N; Caner M; Sakarcan A; Yeğen BC
    Pharmacol Res; 2006 Jul; 54(1):65-71. PubMed ID: 16584888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Montelukast Ameliorates Scopolamine-induced Alzheimer's Disease: Role on Cholinergic Neurotransmission, Antioxidant Defence System, Neuroinflammation and Expression of BDNF.
    Yerraguravagari B; Penchikala NP; Kolusu AS; Ganesh GS; Konduri P; Nemmani KVS; Samudrala PK
    CNS Neurol Disord Drug Targets; 2024; 23(8):1040-1055. PubMed ID: 37779395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic renal failure-induced multiple-organ injury in rats is alleviated by the selective CysLT1 receptor antagonist montelukast.
    Sener G; Sakarcan A; Sehirli O; Ekşioğlu-Demiralp E; Sener E; Ercan F; Gedik N; Yeğen BC
    Prostaglandins Other Lipid Mediat; 2007 Jun; 83(4):257-67. PubMed ID: 17499745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cysteinyl leukotriene receptor antagonist epigenetically modulates cytokine expression and maturation of human myeloid dendritic cells.
    Kuo CH; Yang SN; Kuo HF; Lee MS; Huang MY; Huang SK; Lin YC; Hsieh CC; Hung CH
    Pulm Pharmacol Ther; 2016 Aug; 39():28-37. PubMed ID: 27312202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Montelukast and irbesartan ameliorate metabolic and hepatic disorders in fructose-induced metabolic syndrome in rats.
    Ibrahim MA; Amin EF; Ibrahim SA; Abdelzaher WY; Abdelrahman AM
    Eur J Pharmacol; 2014 Feb; 724():204-10. PubMed ID: 24370493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective effect of melatonin versus montelukast in cisplatin-induced seminiferous tubule damage in rats.
    El-Shafaei A; Abdelmaksoud R; Elshorbagy A; Zahran N; Elabd R
    Andrologia; 2018 Nov; 50(9):e13077. PubMed ID: 30019386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renoprotective effects of montelukast, a cysteinyl leukotriene receptor antagonist, against methotrexate-induced kidney damage in rats.
    Abdel-Raheem IT; Khedr NF
    Naunyn Schmiedebergs Arch Pharmacol; 2014 Apr; 387(4):341-53. PubMed ID: 24363042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The leukotriene d4 receptor antagonist, montelukast, inhibits mast cell degranulation in the dermis induced by water avoidance stress.
    Cikler E; Ersoy Y; Cetinel S; Ercan F
    Acta Histochem; 2009; 111(2):112-8. PubMed ID: 18617226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-Allergic Drug Suppressed Pancreatic Carcinogenesis via Down-Regulation of Cellular Proliferation.
    Kachi K; Kato H; Naiki-Ito A; Komura M; Nagano-Matsuo A; Naitoh I; Hayashi K; Kataoka H; Inaguma S; Takahashi S
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Montelukast rescues primary neurons against Aβ1-42-induced toxicity through inhibiting CysLT1R-mediated NF-κB signaling.
    Lai J; Mei ZL; Wang H; Hu M; Long Y; Miao MX; Li N; Hong H
    Neurochem Int; 2014 Sep; 75():26-31. PubMed ID: 24879954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice.
    Michael J; Zirknitzer J; Unger MS; Poupardin R; Rieß T; Paiement N; Zerbe H; Hutter-Paier B; Reitsamer H; Aigner L
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Montelukast abrogates rhabdomyolysis-induced acute renal failure via rectifying detrimental changes in antioxidant profile and systemic cytokines and apoptotic factors production.
    Helmy MM; El-Gowelli HM
    Eur J Pharmacol; 2012 May; 683(1-3):294-300. PubMed ID: 22449377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of a cysteinyl leukotriene receptor antagonist on experimental emphysema and asthma combined with emphysema.
    Ikeda G; Miyahara N; Koga H; Fuchimoto Y; Waseda K; Kurimoto E; Taniguchi A; Tanimoto Y; Kataoka M; Tanimoto M; Kanehiro A
    Am J Respir Cell Mol Biol; 2014 Jan; 50(1):18-29. PubMed ID: 23937413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Montelukast, a selective cysteinyl leukotriene receptor 1 antagonist, reduces cerulein-induced pancreatic injury in rats.
    Ozkan E; Akyüz C; Sehirli AO; Topaloğlu U; Ercan F; Sener G
    Pancreas; 2010 Oct; 39(7):1041-6. PubMed ID: 20467345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute effects of the cys-leukotriene-1 receptor antagonist, montelukast, on experimental colitis in rats.
    Holma R; Salmenperä P; Riutta A; Virtanen I; Korpela R; Vapaatalo H
    Eur J Pharmacol; 2001 Oct; 429(1-3):309-18. PubMed ID: 11698051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leukotriene D4 receptor antagonist montelukast alleviates water avoidance stress-induced degeneration of the gastrointestinal mucosa.
    Ersoy Y; Cikler E; Cetinel S; Sener G; Ercan F
    Prostaglandins Leukot Essent Fatty Acids; 2008 Mar; 78(3):189-97. PubMed ID: 18387287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathophysiological role of mast cells in collagen-induced arthritis: study with a cysteinyl leukotriene receptor antagonist, montelukast.
    Shiota N; Shimoura K; Okunishi H
    Eur J Pharmacol; 2006 Oct; 548(1-3):158-66. PubMed ID: 16949072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cysteinyl-leukotriene receptor antagonist montelukast decreases blood-brain barrier permeability but does not prevent oedema formation in traumatic brain injury.
    Biber N; Toklu HZ; Solakoglu S; Gultomruk M; Hakan T; Berkman Z; Dulger FG
    Brain Inj; 2009 Jun; 23(6):577-84. PubMed ID: 19484631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cysteinyl leukotriene receptor (CysLT) antagonists decrease pentylenetetrazol-induced seizures and blood-brain barrier dysfunction.
    Lenz QF; Arroyo DS; Temp FR; Poersch AB; Masson CJ; Jesse AC; Marafiga JR; Reschke CR; Iribarren P; Mello CF
    Neuroscience; 2014 Sep; 277():859-71. PubMed ID: 25090924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.